The first Clinically Validated AI powered Diabetes Assistant
Diabetes mellitus, a common chronic disease that is associated with high blood glucose (also called blood sugar) can lead to potentially fatal health complications. Globally, 415 million people were diagnosed with diabetes in 2015...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto DIABETESMART
Duración del proyecto: 3 meses
Fecha Inicio: 2019-05-20
Fecha Fin: 2019-08-31
Líder del proyecto
HEDIA IVS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Diabetes mellitus, a common chronic disease that is associated with high blood glucose (also called blood sugar) can lead to potentially fatal health complications. Globally, 415 million people were diagnosed with diabetes in 2015, estimated to reach 642 million by 2040. In Europe disease prevalence is high, 66 million people were diagnosed in 2017, estimate to reach 81 million people by 2045, with 28,200 children (bellow 19 years old) diagnosed each year. Diabetes requires long-life care management from a physician care team and patient daily self-management. Improvement of diabetes self-care was shown when people with diabetes used mobile phone application. Yet, the challenge is to identify a clinical relevant App between the thousand diabetes management applications available in the market. Hedia, a Danish pioneer start-up company was founded with the mission to make life easier for people with diabetes. Based on the current challenges, we have developed a mobile platform for the daily diabetes management that outperforms the current stat-of-the-art: clinically validated Class IIA compliant to Europes’s new MDR; an artificial intelligent powered that provides tailored recommendations based on the individuals lifestyle and country context; integrate the user’s blood medical device and wearable of choice and other advanced features that enable people with diabetes live a normal life.
DIABETESMART project targets the diabetes care market, which has an estimate value of €69.10B in 2016, forecast to reach €137.28B by 2022 with a 12.4% CAGR (2016-2022). We aim to offer DIABETESMART to corporates -who will obtain further revenues of €18M per year- and to people with diabetes who will benefit from real-time clinically meaningful insights based on AI by 2021. We foresee to reach revenues of €26.6 million with €75.1 million in cumulative profits and increase our team to at least 25 employees (from current 11) by 2026.